Jeffrey Shirley
Clinical Nurse Specialist · Newnan, GANPI 1689811200
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 99.2% of the total across 152 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 30 manufacturers, the largest accounting for just 20.0% — the pattern of someone who eats at a lot of different presentations. 2025 is the largest year on record at $1,133, 6.2 times the $184 reported in 2021.
Across 152 payments — averaging $20.23 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Novo Nordisk$614
- Lilly USA, LLC$402
- Sanofi-aventis U.S. LLC$355
- Radius Health, Inc.$220
- Dexcom, Inc.$168
- Corcept Therapeutics$164
- plus $1K from 24 others
What the payments were for
- Food & beverage$3,05199%
- Education$241%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Novo Nordisk | 41 | $614 |
| Lilly USA, LLC | 16 | $402 |
| Sanofi-aventis U.S. LLC | 12 | $355 |
| Radius Health, Inc. | 8 | $220 |
| Dexcom, Inc. | 9 | $168 |
| Corcept Therapeutics | 7 | $164 |
| Xeris Pharmaceuticals, Inc. | 7 | $150 |
| Boehringer Ingelheim | 6 | $139 |
| Tandem Diabetes Care, Inc. | 7 | $124 |
| AstraZeneca(2 entities) | 4 | $76 |
| Abbott | 3 | $72 |
| Pfizer | 3 | $61 |
| Sequel Med Tech, LLC | 3 | $61 |
| AbbVie | 4 | $57 |
| Amgen | 3 | $52 |
| Medtronic | 2 | $52 |
| Ascendis Pharma Endocrinology Inc | 2 | $41 |
| Novartis | 2 | $36 |
| IBSA Pharma Inc. | 2 | $33 |
| Amphastar Pharmaceuticals, Inc. | 1 | $25 |
| Alvogen Inc | 1 | $24 |
| Mannkind Corporation | 1 | $24 |
| Soleno Therapeutics, Inc. | 1 | $23 |
| Esperion Therapeutics, Inc. | 1 | $18 |
| Antares Pharma, Inc. | 1 | $17 |
| Merck | 1 | $15 |
| Cequr Corporation | 1 | $15 |
| Tolmar, Inc. | 1 | $13 |
| Intuity Medical Inc | 1 | $13 |
| Acella Pharmaceuticals, LLC | 1 | $12 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- MOUNJARO$122
How this compares
Too few clinical nurse specialist providers in Georgiato place this figure against a meaningful peer group, so we don't.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 209 | $318,569 |
| MounjaroTirzepatide | 99 | $156,153 |
| JardianceEmpagliflozin | 130 | $142,123 |
| RybelsusSemaglutide | 32 | $73,979 |
| Tresiba Flextouch U-200Insulin Degludec | 51 | $51,085 |
| TrulicityDulaglutide | 36 | $50,950 |
| Toujeo Max SolostarInsulin Glargine,hum.Rec.Anlog | 46 | $48,997 |
| Tresiba Flextouch U-100Insulin Degludec | 62 | $41,739 |
| Synjardy XrEmpagliflozin/Metformin Hcl | 25 | $35,322 |
| Soliqua 100-33Insulin Glargine/Lixisenatide | 27 | $29,140 |
| FarxigaDapagliflozin Propanediol | 20 | $25,380 |
| Fiasp FlextouchInsulin Aspart (Niacinamide) | 32 | $22,082 |
| Toujeo SolostarInsulin Glargine,hum.Rec.Anlog | 29 | $21,930 |
| JanuviaSitagliptin Phosphate | 14 | $19,411 |
| Humalog Kwikpen U-100Insulin Lispro | 51 | $17,210 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Novo NordiskOzempic, Rybelsus, Novolog | $614 | $396,494257 claims |
| Lilly USA, LLCMounjaro, Trulicity | $402 | $207,103135 claims |
| Boehringer IngelheimJardiance, Synjardy Xr, Tradjenta | $139 | $193,150172 claims |
| Sanofi-aventis U.S. LLCSoliqua 100-33, Lantus | $355 | $30,69044 claims |
| AstraZenecaFarxiga | $76 | $25,38020 claims |
| MerckJanuvia | $15 | $19,41114 claims |
| AbbVieSynthroid | $57 | $3,15443 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. There are too few clinical nurse specialist providers in Georgiaon file to place this against a meaningful peer group, so we don't.
Other clinical nurse specialist in Newnan
- Kathryn ButlerRockmart$2K
- Hallie MarinoAtlanta$199
- Elizabeth MooreDuluth$102
- Danielle LaidlerStockbridge$92
- Melissa DeckertAtlanta$92
- Lynn StamegnaAtlanta$23
- Sarah Carsonla Fayette$14
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.